A translational framework to DELIVER nanomedicines to the clinic

Nanomedicines have created a paradigm shift in healthcare. Yet fundamental barriers still exist that prevent or delay the clinical translation of nanomedicines. Critical hurdles inhibiting clinical success include poor understanding of nanomedicines' physicochemical properties, limited exposure...

Full description

Saved in:
Bibliographic Details
Published inNature nanotechnology
Main Authors Joyce, Paul, Allen, Christine J, Alonso, María José, Ashford, Marianne, Bradbury, Michelle S, Germain, Matthieu, Kavallaris, Maria, Langer, Robert, Lammers, Twan, Peracchia, Maria Teresa, Popat, Amirali, Prestidge, Clive A, Rijcken, Cristianne J F, Sarmento, Bruno, Schmid, Ruth B, Schroeder, Avi, Subramaniam, Santhni, Thorn, Chelsea R, Whitehead, Kathryn A, Zhao, Chun-Xia, Santos, Hélder A
Format Journal Article
LanguageEnglish
Published England 06.09.2024
Online AccessGet full text

Cover

Abstract Nanomedicines have created a paradigm shift in healthcare. Yet fundamental barriers still exist that prevent or delay the clinical translation of nanomedicines. Critical hurdles inhibiting clinical success include poor understanding of nanomedicines' physicochemical properties, limited exposure in the cell or tissue of interest, poor reproducibility of preclinical outcomes in clinical trials, and biocompatibility concerns. Barriers that delay translation include industrial scale-up or scale-down and good manufacturing practices, funding and navigating the regulatory environment. Here we propose the DELIVER framework comprising the core principles to be realized during preclinical development to promote clinical investigation of nanomedicines. The proposed framework comes with design, experimental, manufacturing, preclinical, clinical, regulatory and business considerations, which we recommend investigators to carefully review during early-stage nanomedicine design and development to mitigate risk and enable timely clinical success. By reducing development time and clinical trial failure, it is envisaged that this framework will help accelerate the clinical translation and maximize the impact of nanomedicines.
AbstractList Nanomedicines have created a paradigm shift in healthcare. Yet fundamental barriers still exist that prevent or delay the clinical translation of nanomedicines. Critical hurdles inhibiting clinical success include poor understanding of nanomedicines' physicochemical properties, limited exposure in the cell or tissue of interest, poor reproducibility of preclinical outcomes in clinical trials, and biocompatibility concerns. Barriers that delay translation include industrial scale-up or scale-down and good manufacturing practices, funding and navigating the regulatory environment. Here we propose the DELIVER framework comprising the core principles to be realized during preclinical development to promote clinical investigation of nanomedicines. The proposed framework comes with design, experimental, manufacturing, preclinical, clinical, regulatory and business considerations, which we recommend investigators to carefully review during early-stage nanomedicine design and development to mitigate risk and enable timely clinical success. By reducing development time and clinical trial failure, it is envisaged that this framework will help accelerate the clinical translation and maximize the impact of nanomedicines.
Nanomedicines have created a paradigm shift in healthcare. Yet fundamental barriers still exist that prevent or delay the clinical translation of nanomedicines. Critical hurdles inhibiting clinical success include poor understanding of nanomedicines' physicochemical properties, limited exposure in the cell or tissue of interest, poor reproducibility of preclinical outcomes in clinical trials, and biocompatibility concerns. Barriers that delay translation include industrial scale-up or scale-down and good manufacturing practices, funding and navigating the regulatory environment. Here we propose the DELIVER framework comprising the core principles to be realized during preclinical development to promote clinical investigation of nanomedicines. The proposed framework comes with design, experimental, manufacturing, preclinical, clinical, regulatory and business considerations, which we recommend investigators to carefully review during early-stage nanomedicine design and development to mitigate risk and enable timely clinical success. By reducing development time and clinical trial failure, it is envisaged that this framework will help accelerate the clinical translation and maximize the impact of nanomedicines.Nanomedicines have created a paradigm shift in healthcare. Yet fundamental barriers still exist that prevent or delay the clinical translation of nanomedicines. Critical hurdles inhibiting clinical success include poor understanding of nanomedicines' physicochemical properties, limited exposure in the cell or tissue of interest, poor reproducibility of preclinical outcomes in clinical trials, and biocompatibility concerns. Barriers that delay translation include industrial scale-up or scale-down and good manufacturing practices, funding and navigating the regulatory environment. Here we propose the DELIVER framework comprising the core principles to be realized during preclinical development to promote clinical investigation of nanomedicines. The proposed framework comes with design, experimental, manufacturing, preclinical, clinical, regulatory and business considerations, which we recommend investigators to carefully review during early-stage nanomedicine design and development to mitigate risk and enable timely clinical success. By reducing development time and clinical trial failure, it is envisaged that this framework will help accelerate the clinical translation and maximize the impact of nanomedicines.
Author Joyce, Paul
Schroeder, Avi
Alonso, María José
Whitehead, Kathryn A
Peracchia, Maria Teresa
Zhao, Chun-Xia
Langer, Robert
Rijcken, Cristianne J F
Subramaniam, Santhni
Popat, Amirali
Prestidge, Clive A
Schmid, Ruth B
Santos, Hélder A
Thorn, Chelsea R
Ashford, Marianne
Germain, Matthieu
Lammers, Twan
Bradbury, Michelle S
Allen, Christine J
Kavallaris, Maria
Sarmento, Bruno
Author_xml – sequence: 1
  givenname: Paul
  orcidid: 0000-0003-3619-7901
  surname: Joyce
  fullname: Joyce, Paul
  email: paul.joyce@unisa.edu.au
  organization: Centre for Pharmaceutical Innovation, UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia. paul.joyce@unisa.edu.au
– sequence: 2
  givenname: Christine J
  surname: Allen
  fullname: Allen, Christine J
  organization: Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
– sequence: 3
  givenname: María José
  orcidid: 0000-0001-7187-9567
  surname: Alonso
  fullname: Alonso, María José
  organization: Department of Pharmacology, Pharmacy and Pharmaceutical Technology, School of Pharmacy, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
– sequence: 4
  givenname: Marianne
  surname: Ashford
  fullname: Ashford, Marianne
  organization: Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, UK
– sequence: 5
  givenname: Michelle S
  orcidid: 0000-0003-3147-4391
  surname: Bradbury
  fullname: Bradbury, Michelle S
  organization: Molecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medical College, New York, NY, USA
– sequence: 6
  givenname: Matthieu
  surname: Germain
  fullname: Germain, Matthieu
  organization: Curadigm, Nanobiotix, Paris, France
– sequence: 7
  givenname: Maria
  orcidid: 0000-0003-2309-898X
  surname: Kavallaris
  fullname: Kavallaris, Maria
  organization: UNSW Australian Centre for Nanomedicine, Faculty of Engineering, University of New South Wales (UNSW), Sydney, New South Wales, Australia
– sequence: 8
  givenname: Robert
  orcidid: 0000-0003-4255-0492
  surname: Langer
  fullname: Langer, Robert
  organization: Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
– sequence: 9
  givenname: Twan
  orcidid: 0000-0002-1090-6805
  surname: Lammers
  fullname: Lammers, Twan
  organization: Mildred Scheel School of Oncology (MSSO), Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIOABCD), RWTH Aachen University Hospital, Aachen, Germany
– sequence: 10
  givenname: Maria Teresa
  orcidid: 0009-0002-9565-0286
  surname: Peracchia
  fullname: Peracchia, Maria Teresa
  organization: mRNA Center of Excellence, Sanofi R&D, Marcy l'Etoile, France
– sequence: 11
  givenname: Amirali
  orcidid: 0000-0001-5401-3446
  surname: Popat
  fullname: Popat, Amirali
  organization: School of Pharmacy, The University of Queensland, Woolloongabba, Queensland, Australia
– sequence: 12
  givenname: Clive A
  orcidid: 0000-0001-5401-7535
  surname: Prestidge
  fullname: Prestidge, Clive A
  organization: Centre for Pharmaceutical Innovation, UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia
– sequence: 13
  givenname: Cristianne J F
  surname: Rijcken
  fullname: Rijcken, Cristianne J F
  organization: Cristal Therapeutics, Maastricht, The Netherlands
– sequence: 14
  givenname: Bruno
  surname: Sarmento
  fullname: Sarmento, Bruno
  organization: INEB - Institute for Biomedical Engineering, University of Porto, Porto, Portugal
– sequence: 15
  givenname: Ruth B
  orcidid: 0000-0003-4998-7064
  surname: Schmid
  fullname: Schmid, Ruth B
  organization: Department of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim, Norway
– sequence: 16
  givenname: Avi
  surname: Schroeder
  fullname: Schroeder, Avi
  organization: The Louis Family Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa, Israel
– sequence: 17
  givenname: Santhni
  orcidid: 0000-0003-2945-851X
  surname: Subramaniam
  fullname: Subramaniam, Santhni
  organization: Centre for Pharmaceutical Innovation, UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia
– sequence: 18
  givenname: Chelsea R
  surname: Thorn
  fullname: Thorn, Chelsea R
  organization: BioTherapeutics Pharmaceutical Sciences, Pfizer, Andover, MA, USA
– sequence: 19
  givenname: Kathryn A
  orcidid: 0000-0002-0100-7824
  surname: Whitehead
  fullname: Whitehead, Kathryn A
  organization: Department of Chemical Engineering, Carnegie Mellon University, Pittsburgh, PA, USA
– sequence: 20
  givenname: Chun-Xia
  orcidid: 0000-0002-3365-3759
  surname: Zhao
  fullname: Zhao, Chun-Xia
  organization: Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland, Australia
– sequence: 21
  givenname: Hélder A
  orcidid: 0000-0001-7850-6309
  surname: Santos
  fullname: Santos, Hélder A
  email: h.a.santos@umcg.nl, h.a.santos@umcg.nl, h.a.santos@umcg.nl
  organization: Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland. h.a.santos@umcg.nl
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39242807$$D View this record in MEDLINE/PubMed
BookMark eNo9kEtPwzAQhC1URB_wBzigHLkEvH7EyQ1UClSqhISAq-U4GxFI7GKnQvx7Ulp6mpF2ZqT9pmTkvENCzoFeAeX5dRQgM5lSJlIKSopUHZEJKJGnnBdydPC5GpNpjB-USlYwcULGfBCWUzUhN7dJH4yLrekb70yb1MF0-O3DZ9L75G6xWr4tnhNnnO-wamzjMG4P_Tsmtm1cY0_JcW3aiGd7nZHX-8XL_DFdPT0s57er1EIu-lTYXFUCKkFrEMBBKhBYoapKLLOyzAxlCoAxYTOOJYPcYsWzAjlAXfA64zNyudtdB_-1wdjrrokW29Y49JuoOQwMCknlNsp2URt8jAFrvQ5NZ8KPBqq35PSOnB7I6T9yWg2li_3-phxePVT-UfFf089pmg
Cites_doi 10.1136/ijgc-2023-004308
10.1021/acsnano.3c05635
10.1016/j.xphs.2018.10.037
10.1016/j.jcis.2023.03.048
10.1073/pnas.1919755117
10.1002/adma.202309355
10.1080/17460441.2021.1826434
10.1007/s13770-022-00515-8
10.1016/j.addr.2018.05.008
10.1016/j.jconrel.2012.05.042
10.1007/s13346-022-01150-5
10.1007/s13346-021-00911-y
10.1016/j.jconrel.2012.03.020
10.1007/978-1-4939-7352-1_1
10.1007/s13346-020-00740-5
10.1038/nnano.2015.341
10.1208/s12248-019-0329-7
10.1208/s12248-016-9969-z
10.1016/j.matt.2023.02.007
10.2202/1941-6008.1120
10.1126/scitranslmed.aaf5027
10.1208/s12249-014-0177-9
10.1016/j.tips.2022.05.001
10.1038/s41598-019-47270-w
10.1016/j.medj.2022.12.001
10.1200/JCO.2019.37.15_suppl.3026
10.1038/natrevmats.2016.69
10.1038/s41587-022-01485-x
10.1002/adma.201805740
10.3389/fimmu.2022.849759
10.1208/s12248-019-0292-3
10.1158/1078-0432.CCR-16-1990
10.1158/1078-0432.CCR-20-0008
10.1016/j.ijpharm.2021.120962
10.1016/j.addr.2022.114591
10.1016/j.jconrel.2019.05.044
10.1002/adhm.202200690
10.1016/j.ijpharm.2021.120554
10.1016/j.phrs.2022.106454
10.1016/S2468-1253(16)30219-9
10.1056/NEJMoa2035389
10.1111/nyas.12403
10.1021/acs.accounts.9b00228
10.2147/IJN.S372477
10.1021/acs.nanolett.3c04171
10.1016/j.jconrel.2020.07.007
10.1016/j.mattod.2023.02.009
10.1039/c2ib20117h
10.1038/s41551-024-01197-4
10.1038/s41565-023-01371-w
10.1002/smtd.202301300
10.1038/nbt.2609
10.1016/j.jconrel.2023.01.063
10.1021/jacs.0c09029
10.1016/j.it.2023.11.003
10.1007/s40290-020-00334-z
10.1016/j.biotechadv.2017.08.003
10.1016/j.technovation.2020.102153
10.1111/nyas.14662
10.1023/A:1011199028318
10.1038/s41578-023-00552-2
10.1038/s41416-019-0391-z
10.1016/j.nantod.2019.06.004
10.1172/JCI175824
10.1093/ajhp/zxab048
10.1038/s41565-023-01455-7
10.2165/00002018-200124120-00004
10.1016/j.addr.2021.113829
10.1038/nrc3972
10.1039/D0BM00558D
10.1002/wnan.1546
10.1038/s41551-018-0314-y
10.1038/s41565-018-0246-4
10.1038/s41568-022-00496-9
10.1016/j.apsb.2022.02.025
10.1016/j.conctc.2018.08.001
10.1016/j.nano.2015.02.004
10.1016/j.addr.2016.04.025
10.4103/0976-500X.72351
10.1038/s41565-019-0496-9
10.1200/JCO.2019.37.15_suppl.3093
10.1038/s41573-021-00283-5
10.1021/acsnano.5b03300
10.1016/j.copbio.2023.103045
ContentType Journal Article
Copyright 2024. Springer Nature Limited.
Copyright_xml – notice: 2024. Springer Nature Limited.
DBID NPM
AAYXX
CITATION
7X8
DOI 10.1038/s41565-024-01754-7
DatabaseName PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Engineering
EISSN 1748-3395
ExternalDocumentID 10_1038_s41565_024_01754_7
39242807
Genre Journal Article
Review
GrantInformation_xml – fundername: Cancer Council NSW (Cancer Council New South Wales)
  grantid: 2020797
– fundername: Deutsche Forschungsgemeinschaft (German Research Foundation)
  grantid: SFB1066
– fundername: Academy of Finland (Suomen Akatemia)
  grantid: 331151
– fundername: Department of Health | National Health and Medical Research Council (NHMRC)
  grantid: Synergy Grant 2019056
– fundername: Department of Health | National Health and Medical Research Council (NHMRC)
  grantid: Investigator Grant APP2008698
– fundername: Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research)
  grantid: PP-TNBC
– fundername: Hospital Research Foundation (The Hospital Research Foundation)
  grantid: 2022-CF-EMCR-004-25314
– fundername: Deutsche Forschungsgemeinschaft (German Research Foundation)
  grantid: LA2937/4-1
– fundername: Department of Health | National Health and Medical Research Council (NHMRC)
  grantid: Investigator Grant 2016464
– fundername: Deutsche Forschungsgemeinschaft (German Research Foundation)
  grantid: KFO5011
GroupedDBID ---
-~X
0R~
123
29M
39C
4.4
53G
5BI
6OB
70F
7X7
AAEEF
AARCD
AAYZH
AAZLF
ABJNI
ABLJU
ACGFS
ACIWK
ACPRK
ADBBV
AENEX
AFBBN
AFLOW
AFRAH
AFSHS
AFWHJ
AGAYW
AGEZK
AGHTU
AHBCP
AHMBA
AHOSX
AHSBF
AIBTJ
ALFFA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ARAPS
ARMCB
ASPBG
AVWKF
AXYYD
AZFZN
BENPR
BHPHI
BKKNO
CS3
DU5
EBS
EE.
EXGXG
F5P
FEDTE
FQGFK
FSGXE
HCIFZ
HVGLF
HZ~
NNMJJ
NPM
O9-
ODYON
P2P
RNS
RNT
RNTTT
SHXYY
SIXXV
SNYQT
TAOOD
TBHMF
TDRGL
TSG
AAYXX
ABVXF
CITATION
7X8
ID FETCH-LOGICAL-c184t-4c87d41d40f141315714ede7dbeb6bb6a02711224c63eb218ced369e311f93f63
ISSN 1748-3387
1748-3395
IngestDate Sat Oct 26 04:01:51 EDT 2024
Wed Sep 11 13:28:56 EDT 2024
Tue Oct 29 09:10:36 EDT 2024
IsPeerReviewed true
IsScholarly true
Language English
License 2024. Springer Nature Limited.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c184t-4c87d41d40f141315714ede7dbeb6bb6a02711224c63eb218ced369e311f93f63
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ORCID 0000-0001-5401-7535
0000-0001-7850-6309
0000-0002-1090-6805
0000-0003-4255-0492
0000-0003-2945-851X
0000-0003-2309-898X
0009-0002-9565-0286
0000-0002-0100-7824
0000-0001-7187-9567
0000-0001-5401-3446
0000-0003-3147-4391
0000-0003-4998-7064
0000-0002-3365-3759
0000-0003-3619-7901
PMID 39242807
PQID 3101795056
PQPubID 23479
ParticipantIDs proquest_miscellaneous_3101795056
crossref_primary_10_1038_s41565_024_01754_7
pubmed_primary_39242807
PublicationCentury 2000
PublicationDate 2024-Sep-06
2024-09-06
20240906
PublicationDateYYYYMMDD 2024-09-06
PublicationDate_xml – month: 09
  year: 2024
  text: 2024-Sep-06
  day: 06
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Nature nanotechnology
PublicationTitleAlternate Nat Nanotechnol
PublicationYear 2024
References X Shan (1754_CR7) 2022; 12
YS Youn (1754_CR3) 2018; 130
M Mahmoudi (1754_CR33) 2023; 8
K Park (1754_CR1) 2019; 305
C Stillhart (1754_CR28) 2019; 21
E Hemmrich (1754_CR68) 2023; 18
N Chaudhary (1754_CR82) 2021; 20
VL Beraldo-de-Araújo (1754_CR21) 2019; 9
S Tinkle (1754_CR66) 2014; 1313
K Shitara (1754_CR59) 2017; 2
R Elnathan (1754_CR74) 2022; 17
R Langer (1754_CR78) 2013; 31
M Faria (1754_CR84) 2018; 13
S Pan (1754_CR47) 2024; 45
B Ingrid (1754_CR65) 2023; 33
H He (1754_CR37) 2019; 52
S Shin (1754_CR48) 2023; 20
Y-H Zuo (1754_CR50) 2022; 184
1754_CR8
J-N May (1754_CR57) 2024
C Kilkenny (1754_CR85) 2010; 1
PH Zushin (1754_CR41) 2023; 133
1754_CR12
SN Goodman (1754_CR43) 2016; 8
F Atrafi (1754_CR64) 2020; 26
M Hadjidemetriou (1754_CR89) 2015; 9
1754_CR55
G Troiano (1754_CR26) 2016; 18
VJ Thomas (1754_CR76) 2020; 96-97
NS Arden (1754_CR92) 2021; 602
IHC Miedema (1754_CR62) 2019; 37
SN Bhatia (1754_CR2) 2022; 22
1754_CR9
DB Fogel (1754_CR70) 2018; 11
J Mi (1754_CR49) 2022; 13
1754_CR52
P Jain (1754_CR35) 2017; 35
1754_CR95
TG Agnihotri (1754_CR36) 2023; 354
L Milane (1754_CR10) 2021; 11
RM Crist (1754_CR19) 2013; 5
RM Hoffman (1754_CR40) 2015; 15
JB Hertig (1754_CR69) 2021; 78
M-P Mast (1754_CR27) 2021; 179
F Angeli (1754_CR58) 2020; 34
D Yuan (1754_CR29) 2019; 108
W Ke (1754_CR44) 2022; 191
P Urbán (1754_CR34) 2019; 11
RJ Hickman (1754_CR91) 2023; 6
JM Metselaar (1754_CR13) 2020; 10
M Germain (1754_CR16) 2020; 326
H Young (1754_CR93) 2024; 24
F Tong (1754_CR38) 2024; 85
1754_CR87
AJ Chetwynd (1754_CR88) 2019; 28
S Subramaniam (1754_CR32) 2023; 641
T Lammers (1754_CR5) 2016; 1
M Kendall (1754_CR18) 2016; 11
N Wang (1754_CR22) 2021; 607
KJ Harrington (1754_CR25) 2001; 12
M Jung (1754_CR30) 2022; 11
JPA Ioannidis (1754_CR42) 2018; 2
1754_CR86
Y Chen (1754_CR51) 2023; 63
JI Hare (1754_CR15) 2017; 108
P Zhang (1754_CR39) 2023; 4
S Prokesch (1754_CR79) 2017; 95
ER Gold (1754_CR83) 2022; 40
G Berrecoso (1754_CR23) 2022; 12
Y Kosaka (1754_CR61) 2022; 17
RK Ramanathan (1754_CR56) 2017; 23
Z Ban (1754_CR90) 2020; 117
R Foulkes (1754_CR67) 2020; 8
J Li (1754_CR20) 2020; 143
DN Waterhouse (1754_CR24) 2001; 24
Y Barenholz (1754_CR6) 2012; 160
R Cai (1754_CR31) 2019; 31
R Paliwal (1754_CR45) 2014; 15
H Tang (1754_CR14) 2023; 18
GH Zhu (1754_CR17) 2022; 43
HS Leong (1754_CR4) 2019; 14
Y Fujiwara (1754_CR60) 2019; 120
GA Van Norman (1754_CR72) 2016; 1
1754_CR77
AM López-Estévez (1754_CR53) 2023; 36
F Atrafi (1754_CR63) 2019; 37
LR Baden (1754_CR80) 2021; 384
MAW Eaton (1754_CR81) 2015; 11
1754_CR71
K Klein (1754_CR73) 2021; 1502
Q Sun (1754_CR54) 2012; 164
A Park (1754_CR75) 2022; 17
JSB de Vlieger (1754_CR94) 2019; 21
X Liu (1754_CR46) 2023; 17
S Bhattacharjee (1754_CR11) 2021; 16
References_xml – volume: 33
  start-page: 1247
  year: 2023
  ident: 1754_CR65
  publication-title: Int. J. Gynecol. Cancer
  doi: 10.1136/ijgc-2023-004308
  contributor:
    fullname: B Ingrid
– ident: 1754_CR86
– volume: 17
  start-page: 19550
  year: 2023
  ident: 1754_CR46
  publication-title: ACS Nano
  doi: 10.1021/acsnano.3c05635
  contributor:
    fullname: X Liu
– volume: 108
  start-page: 58
  year: 2019
  ident: 1754_CR29
  publication-title: J. Pharm. Sci.
  doi: 10.1016/j.xphs.2018.10.037
  contributor:
    fullname: D Yuan
– volume: 641
  start-page: 36
  year: 2023
  ident: 1754_CR32
  publication-title: J. Colloid Interface Sci.
  doi: 10.1016/j.jcis.2023.03.048
  contributor:
    fullname: S Subramaniam
– volume: 117
  start-page: 10492
  year: 2020
  ident: 1754_CR90
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.1919755117
  contributor:
    fullname: Z Ban
– volume: 36
  start-page: 2309355
  year: 2023
  ident: 1754_CR53
  publication-title: Adv. Mater.
  doi: 10.1002/adma.202309355
  contributor:
    fullname: AM López-Estévez
– volume: 16
  start-page: 235
  year: 2021
  ident: 1754_CR11
  publication-title: Expert Opin. Drug Discov.
  doi: 10.1080/17460441.2021.1826434
  contributor:
    fullname: S Bhattacharjee
– volume: 20
  start-page: 371
  year: 2023
  ident: 1754_CR48
  publication-title: Tissue Eng. Regen. Med.
  doi: 10.1007/s13770-022-00515-8
  contributor:
    fullname: S Shin
– volume: 130
  start-page: 3
  year: 2018
  ident: 1754_CR3
  publication-title: Adv. Drug Deliv. Rev.
  doi: 10.1016/j.addr.2018.05.008
  contributor:
    fullname: YS Youn
– volume: 164
  start-page: 156
  year: 2012
  ident: 1754_CR54
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2012.05.042
  contributor:
    fullname: Q Sun
– volume: 12
  start-page: 2865
  year: 2022
  ident: 1754_CR23
  publication-title: Drug Deliv. Transl. Res.
  doi: 10.1007/s13346-022-01150-5
  contributor:
    fullname: G Berrecoso
– volume: 11
  start-page: 1309
  year: 2021
  ident: 1754_CR10
  publication-title: Drug Deliv. Transl. Res.
  doi: 10.1007/s13346-021-00911-y
  contributor:
    fullname: L Milane
– volume: 160
  start-page: 117
  year: 2012
  ident: 1754_CR6
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2012.03.020
  contributor:
    fullname: Y Barenholz
– ident: 1754_CR12
  doi: 10.1007/978-1-4939-7352-1_1
– volume: 10
  start-page: 721
  year: 2020
  ident: 1754_CR13
  publication-title: Drug Deliv. Transl. Res.
  doi: 10.1007/s13346-020-00740-5
  contributor:
    fullname: JM Metselaar
– volume: 11
  start-page: 206
  year: 2016
  ident: 1754_CR18
  publication-title: Nat. Nanotechnol.
  doi: 10.1038/nnano.2015.341
  contributor:
    fullname: M Kendall
– volume: 21
  start-page: 56
  year: 2019
  ident: 1754_CR94
  publication-title: AAPS J.
  doi: 10.1208/s12248-019-0329-7
  contributor:
    fullname: JSB de Vlieger
– volume: 18
  start-page: 1354
  year: 2016
  ident: 1754_CR26
  publication-title: AAPS J.
  doi: 10.1208/s12248-016-9969-z
  contributor:
    fullname: G Troiano
– volume: 6
  start-page: 1071
  year: 2023
  ident: 1754_CR91
  publication-title: Matter
  doi: 10.1016/j.matt.2023.02.007
  contributor:
    fullname: RJ Hickman
– ident: 1754_CR95
  doi: 10.2202/1941-6008.1120
– volume: 1
  start-page: 170
  year: 2016
  ident: 1754_CR72
  publication-title: J. Am. Coll. Cardiol.
  contributor:
    fullname: GA Van Norman
– volume: 8
  start-page: 341ps12
  year: 2016
  ident: 1754_CR43
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.aaf5027
  contributor:
    fullname: SN Goodman
– volume: 15
  start-page: 1527
  year: 2014
  ident: 1754_CR45
  publication-title: AAPS PharmSciTech
  doi: 10.1208/s12249-014-0177-9
  contributor:
    fullname: R Paliwal
– volume: 43
  start-page: 709
  year: 2022
  ident: 1754_CR17
  publication-title: Trends Pharmacol. Sci.
  doi: 10.1016/j.tips.2022.05.001
  contributor:
    fullname: GH Zhu
– volume: 9
  year: 2019
  ident: 1754_CR21
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-019-47270-w
  contributor:
    fullname: VL Beraldo-de-Araújo
– volume: 4
  start-page: 147
  year: 2023
  ident: 1754_CR39
  publication-title: Med
  doi: 10.1016/j.medj.2022.12.001
  contributor:
    fullname: P Zhang
– volume: 37
  start-page: 3026
  year: 2019
  ident: 1754_CR63
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2019.37.15_suppl.3026
  contributor:
    fullname: F Atrafi
– volume: 1
  start-page: 16069
  year: 2016
  ident: 1754_CR5
  publication-title: Nat. Rev. Mater.
  doi: 10.1038/natrevmats.2016.69
  contributor:
    fullname: T Lammers
– volume: 40
  start-page: 1428
  year: 2022
  ident: 1754_CR83
  publication-title: Nat. Biotechnol.
  doi: 10.1038/s41587-022-01485-x
  contributor:
    fullname: ER Gold
– volume: 31
  start-page: 1805740
  year: 2019
  ident: 1754_CR31
  publication-title: Adv. Mater.
  doi: 10.1002/adma.201805740
  contributor:
    fullname: R Cai
– ident: 1754_CR77
– volume: 13
  start-page: 849759
  year: 2022
  ident: 1754_CR49
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2022.849759
  contributor:
    fullname: J Mi
– volume: 21
  start-page: 19
  year: 2019
  ident: 1754_CR28
  publication-title: AAPS
  doi: 10.1208/s12248-019-0292-3
  contributor:
    fullname: C Stillhart
– volume: 23
  start-page: 3638
  year: 2017
  ident: 1754_CR56
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-16-1990
  contributor:
    fullname: RK Ramanathan
– volume: 26
  start-page: 3537
  year: 2020
  ident: 1754_CR64
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-20-0008
  contributor:
    fullname: F Atrafi
– volume: 607
  start-page: 120962
  year: 2021
  ident: 1754_CR22
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2021.120962
  contributor:
    fullname: N Wang
– volume: 191
  start-page: 114591
  year: 2022
  ident: 1754_CR44
  publication-title: Adv. Drug Deliv. Rev.
  doi: 10.1016/j.addr.2022.114591
  contributor:
    fullname: W Ke
– ident: 1754_CR8
– ident: 1754_CR87
– volume: 305
  start-page: 221
  year: 2019
  ident: 1754_CR1
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2019.05.044
  contributor:
    fullname: K Park
– volume: 11
  start-page: 2200690
  year: 2022
  ident: 1754_CR30
  publication-title: Adv. Healthc. Mater.
  doi: 10.1002/adhm.202200690
  contributor:
    fullname: M Jung
– volume: 602
  start-page: 120554
  year: 2021
  ident: 1754_CR92
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2021.120554
  contributor:
    fullname: NS Arden
– volume: 184
  start-page: 106454
  year: 2022
  ident: 1754_CR50
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2022.106454
  contributor:
    fullname: Y-H Zuo
– volume: 2
  start-page: 277
  year: 2017
  ident: 1754_CR59
  publication-title: Lancet Gastroenterol. Hepatol.
  doi: 10.1016/S2468-1253(16)30219-9
  contributor:
    fullname: K Shitara
– volume: 384
  start-page: 403
  year: 2021
  ident: 1754_CR80
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2035389
  contributor:
    fullname: LR Baden
– volume: 1313
  start-page: 35
  year: 2014
  ident: 1754_CR66
  publication-title: Ann. N. Y. Acad. Sci.
  doi: 10.1111/nyas.12403
  contributor:
    fullname: S Tinkle
– volume: 52
  start-page: 2445
  year: 2019
  ident: 1754_CR37
  publication-title: Acc. Chem. Res.
  doi: 10.1021/acs.accounts.9b00228
  contributor:
    fullname: H He
– ident: 1754_CR55
– volume: 17
  start-page: 4567
  year: 2022
  ident: 1754_CR61
  publication-title: Int. J. Nanomed.
  doi: 10.2147/IJN.S372477
  contributor:
    fullname: Y Kosaka
– volume: 24
  start-page: 920
  year: 2024
  ident: 1754_CR93
  publication-title: Nano Lett.
  doi: 10.1021/acs.nanolett.3c04171
  contributor:
    fullname: H Young
– volume: 17
  start-page: 802
  year: 2022
  ident: 1754_CR75
  publication-title: Nat. Nanotechnol.
  contributor:
    fullname: A Park
– volume: 95
  start-page: 134
  year: 2017
  ident: 1754_CR79
  publication-title: Harv. Bus. Rev.
  contributor:
    fullname: S Prokesch
– volume: 326
  start-page: 164
  year: 2020
  ident: 1754_CR16
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2020.07.007
  contributor:
    fullname: M Germain
– volume: 63
  start-page: 8
  year: 2023
  ident: 1754_CR51
  publication-title: Mater. Today
  doi: 10.1016/j.mattod.2023.02.009
  contributor:
    fullname: Y Chen
– volume: 5
  start-page: 66
  year: 2013
  ident: 1754_CR19
  publication-title: Integr. Biol.
  doi: 10.1039/c2ib20117h
  contributor:
    fullname: RM Crist
– year: 2024
  ident: 1754_CR57
  publication-title: Nat. Biomed. Eng.
  doi: 10.1038/s41551-024-01197-4
  contributor:
    fullname: J-N May
– volume: 18
  start-page: 692
  year: 2023
  ident: 1754_CR68
  publication-title: Nat. Nanotechnol.
  doi: 10.1038/s41565-023-01371-w
  contributor:
    fullname: E Hemmrich
– ident: 1754_CR71
– ident: 1754_CR52
  doi: 10.1002/smtd.202301300
– volume: 31
  start-page: 487
  year: 2013
  ident: 1754_CR78
  publication-title: Nat. Biotechnol.
  doi: 10.1038/nbt.2609
  contributor:
    fullname: R Langer
– volume: 354
  start-page: 794
  year: 2023
  ident: 1754_CR36
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2023.01.063
  contributor:
    fullname: TG Agnihotri
– volume: 143
  start-page: 538
  year: 2020
  ident: 1754_CR20
  publication-title: J. Am. Chem. Soc.
  doi: 10.1021/jacs.0c09029
  contributor:
    fullname: J Li
– volume: 45
  start-page: 20
  year: 2024
  ident: 1754_CR47
  publication-title: Trends Immunol.
  doi: 10.1016/j.it.2023.11.003
  contributor:
    fullname: S Pan
– volume: 34
  start-page: 159
  year: 2020
  ident: 1754_CR58
  publication-title: Pharm. Med.
  doi: 10.1007/s40290-020-00334-z
  contributor:
    fullname: F Angeli
– volume: 35
  start-page: 889
  year: 2017
  ident: 1754_CR35
  publication-title: Biotechnol. Adv.
  doi: 10.1016/j.biotechadv.2017.08.003
  contributor:
    fullname: P Jain
– volume: 96-97
  year: 2020
  ident: 1754_CR76
  publication-title: Technovation
  doi: 10.1016/j.technovation.2020.102153
  contributor:
    fullname: VJ Thomas
– volume: 1502
  start-page: 5
  year: 2021
  ident: 1754_CR73
  publication-title: Ann. N. Y. Acad. Sci.
  doi: 10.1111/nyas.14662
  contributor:
    fullname: K Klein
– volume: 12
  start-page: 493
  year: 2001
  ident: 1754_CR25
  publication-title: Ann. Oncol.
  doi: 10.1023/A:1011199028318
  contributor:
    fullname: KJ Harrington
– volume: 8
  start-page: 422
  year: 2023
  ident: 1754_CR33
  publication-title: Nat. Rev. Mater.
  doi: 10.1038/s41578-023-00552-2
  contributor:
    fullname: M Mahmoudi
– volume: 120
  start-page: 475
  year: 2019
  ident: 1754_CR60
  publication-title: Br. J. Cancer
  doi: 10.1038/s41416-019-0391-z
  contributor:
    fullname: Y Fujiwara
– volume: 28
  year: 2019
  ident: 1754_CR88
  publication-title: Nano Today
  doi: 10.1016/j.nantod.2019.06.004
  contributor:
    fullname: AJ Chetwynd
– volume: 133
  year: 2023
  ident: 1754_CR41
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI175824
  contributor:
    fullname: PH Zushin
– volume: 78
  start-page: 1047
  year: 2021
  ident: 1754_CR69
  publication-title: Am. J. Health Syst. Pharm.
  doi: 10.1093/ajhp/zxab048
  contributor:
    fullname: JB Hertig
– ident: 1754_CR9
– volume: 17
  start-page: 807
  year: 2022
  ident: 1754_CR74
  publication-title: Nat. Nanotechnol.
  contributor:
    fullname: R Elnathan
– volume: 18
  start-page: 1067
  year: 2023
  ident: 1754_CR14
  publication-title: Nat. Nanotechnol.
  doi: 10.1038/s41565-023-01455-7
  contributor:
    fullname: H Tang
– volume: 24
  start-page: 903
  year: 2001
  ident: 1754_CR24
  publication-title: Drug. Saf.
  doi: 10.2165/00002018-200124120-00004
  contributor:
    fullname: DN Waterhouse
– volume: 179
  start-page: 113829
  year: 2021
  ident: 1754_CR27
  publication-title: Adv. Drug Deliv. Rev.
  doi: 10.1016/j.addr.2021.113829
  contributor:
    fullname: M-P Mast
– volume: 15
  start-page: 451
  year: 2015
  ident: 1754_CR40
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc3972
  contributor:
    fullname: RM Hoffman
– volume: 8
  start-page: 4653
  year: 2020
  ident: 1754_CR67
  publication-title: Biomater. Sci.
  doi: 10.1039/D0BM00558D
  contributor:
    fullname: R Foulkes
– volume: 11
  start-page: e1546
  year: 2019
  ident: 1754_CR34
  publication-title: Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.
  doi: 10.1002/wnan.1546
  contributor:
    fullname: P Urbán
– volume: 2
  start-page: 797
  year: 2018
  ident: 1754_CR42
  publication-title: Nat. Biomed. Eng.
  doi: 10.1038/s41551-018-0314-y
  contributor:
    fullname: JPA Ioannidis
– volume: 13
  start-page: 777
  year: 2018
  ident: 1754_CR84
  publication-title: Nat. Nanotechnol.
  doi: 10.1038/s41565-018-0246-4
  contributor:
    fullname: M Faria
– volume: 22
  start-page: 550
  year: 2022
  ident: 1754_CR2
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/s41568-022-00496-9
  contributor:
    fullname: SN Bhatia
– volume: 12
  start-page: 3028
  year: 2022
  ident: 1754_CR7
  publication-title: Acta Pharm. Sin. B
  doi: 10.1016/j.apsb.2022.02.025
  contributor:
    fullname: X Shan
– volume: 11
  start-page: 156
  year: 2018
  ident: 1754_CR70
  publication-title: Contemp. Clin. Trials Commun.
  doi: 10.1016/j.conctc.2018.08.001
  contributor:
    fullname: DB Fogel
– volume: 11
  start-page: 983
  year: 2015
  ident: 1754_CR81
  publication-title: Nanomedicine
  doi: 10.1016/j.nano.2015.02.004
  contributor:
    fullname: MAW Eaton
– volume: 108
  start-page: 25
  year: 2017
  ident: 1754_CR15
  publication-title: Adv. Drug Deliv. Rev.
  doi: 10.1016/j.addr.2016.04.025
  contributor:
    fullname: JI Hare
– volume: 1
  start-page: 94
  year: 2010
  ident: 1754_CR85
  publication-title: J. Pharmacol. Pharmacother.
  doi: 10.4103/0976-500X.72351
  contributor:
    fullname: C Kilkenny
– volume: 14
  start-page: 629
  year: 2019
  ident: 1754_CR4
  publication-title: Nat. Nanotechnol.
  doi: 10.1038/s41565-019-0496-9
  contributor:
    fullname: HS Leong
– volume: 37
  start-page: 3093
  year: 2019
  ident: 1754_CR62
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2019.37.15_suppl.3093
  contributor:
    fullname: IHC Miedema
– volume: 20
  start-page: 817
  year: 2021
  ident: 1754_CR82
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/s41573-021-00283-5
  contributor:
    fullname: N Chaudhary
– volume: 9
  start-page: 8142
  year: 2015
  ident: 1754_CR89
  publication-title: ACS Nano
  doi: 10.1021/acsnano.5b03300
  contributor:
    fullname: M Hadjidemetriou
– volume: 85
  start-page: 103045
  year: 2024
  ident: 1754_CR38
  publication-title: Curr. Opin. Biotechnol.
  doi: 10.1016/j.copbio.2023.103045
  contributor:
    fullname: F Tong
SSID ssj0052924
Score 2.5061598
SecondaryResourceType review_article
Snippet Nanomedicines have created a paradigm shift in healthcare. Yet fundamental barriers still exist that prevent or delay the clinical translation of...
SourceID proquest
crossref
pubmed
SourceType Aggregation Database
Index Database
Title A translational framework to DELIVER nanomedicines to the clinic
URI https://www.ncbi.nlm.nih.gov/pubmed/39242807
https://www.proquest.com/docview/3101795056
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwELbaRargUPUJ2wdKpd6Q2zh27N1bAyyCFd1DBRW3yEls9VASRMIBfj3jV7KrBanlEq3iiaOdLxp_9rwQ-qor05OwkhjWxhgzxWMsCZXY1CWJq5TokpsE558LfnzO5hfpxdAE0WaXdMW38u7BvJKnoAr3AFeTJfsfyPaTwg34DfjCFRCG6z9hnJkOD3X7Nxzo6RBpZRjl4ez05Pfs114t6yZ40NtANV1C5DIzXdgKn1a6Wztunze37rB9OZAwM11YhgIFhq7OhzH4z41PBrLO-ENpvA3OL99LtX9CbD2IwYfqffz-FCJhNszK17B2llOwCabUdcxcs8uuCntrdosmIdwEvoiUYbEsDLq9urRIAWdjpkrPsEb1kYNh6DnaSMC0TEZoIzva31-E1TdNQMAnR8FLv6-_chO9CJOscpFHNhiWaJy9Qi_9DiHKHNyv0TNVv0FbS3Uj36IfWbQCfNQDH3VN5IGPVoA3AwB85IB_h86PZmcHx9i3wsAlbME7zMqJqBipWKwJ0A6SCsJUpURVqIIXBZdxIohxkpacqgJoW6kqyqeKEqKnVHP6Ho3qplY7KJKFUlRPhS6FYjKZylhoeIYpeF5LXo7RXlBKfuUqnuQ2UoFOcqfNHLSZW23mYoy-BL3lYJiMt0nWqrlpc2qNvSHYY7TtFNrPFwD48OjIR7Q5fGaf0Ki7vlGfgf51xa5H_B6dh1VC
link.rule.ids 315,783,787,27938,27939
linkProvider Library Specific Holdings
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+translational+framework+to+DELIVER+nanomedicines+to+the+clinic&rft.jtitle=Nature+nanotechnology&rft.au=Joyce%2C+Paul&rft.au=Allen%2C+Christine+J&rft.au=Alonso%2C+Mar%C3%ADa+Jos%C3%A9&rft.au=Ashford%2C+Marianne&rft.date=2024-09-06&rft.eissn=1748-3395&rft_id=info:doi/10.1038%2Fs41565-024-01754-7&rft_id=info%3Apmid%2F39242807&rft.externalDocID=39242807
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1748-3387&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1748-3387&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1748-3387&client=summon